［1］Travis WD，Linnoila RI，Tsokos MG，et al.Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma.An ultrastructural，immunohistochemical，and flow cytometric study of 35 cases［J］.The American Journal of Surgical Pathology，1991，15(6)：529-553.
[2]Karlsson A，Brunnstrom H，Lindquist KE，et al.Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer［J］.Oncotarget，2015，6(26)：22028-22037.
[3]Miyoshi T，Umemura S，Matsumura Y，et al.Genomic profiling of large-cell neuroendocrine carcinoma of the lung［J］.Clinical Cancer Research，2017，23(3)：757-765.
[4]Fournel L，Falcoz PE，Alifano M，et al.Surgical management of pulmonary large cell neuroendocrine carcinomas：A 10-year experience［J］.European Journal of Cardio-thoracic Surgery，2013，43(1)：111-114.
[5]Oberg K，Hellman P，Kwekkeboom D，et al.Neuroendocrine bronchial and thymic tumours：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up［J］.Annals of Oncology，2010，21（Suppl 5）：v220-222.
[6]Horsch D，Schmid KW，Anlauf M，et al.Neuroendocrine tumors of the bronchopulmonary system(typical and atypical carcinoid tumors)：Current strategies in diagnosis and treatment.Conclusions of an expert meeting February 2011 in Weimar，Germany［J］.Oncology Research and Treatment，2014，37(5)：266-276.
[7]Iyoda A，Hiroshima K，Toyozaki T，et al.Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology［J］.Cancer，2001，91(11)：1992-2000.
[8]Fasano M，Della Corte CM，Papaccio F，et al.Pulmonary large-cell neuroendocrine carcinoma：From epidemiology to therapy［J］.Journal of Thoracic Oncology，2015，10(8)：1133-1141.
[9]Lee KW，Lee Y，Oh SW，et al.Large cell neuroendocrine carcinoma of the lung：CT and FDG PET findings［J］.European Journal of Radiology，2015，84(11)：2332-2338.
[10]Yang Wenjia，Han Baohui.The current status of management and research progress of large cell neuroendocrine lung carcinoma's［J］.Oncology Progress，2017，15(11)：1250-1254.
[11]Hiroshima K，Abe S，Ebihara Y，et al.Cytological characteristics of pulmonary large cell neuroendocrine carcinoma［J］.Lung cancer(Amsterdam，Netherlands)，2005，48(3)：331-337.
[12]Fernandez-Cuesta L，Mckay JD.Genomic architecture of lung cancers［J］.Current Opinion in Oncology，2016，28(1)：52-57.
[13]Rekhtman N，Pietanza MC，Hellmann MD，et al.Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets［J］.Clinical Cancer Research，2016，22(14)：3618-3629.
[14]Iyoda A，Makino T，Koezuka S，et al.Treatment options for patients with large cell neuroendocrine carcinoma of the lung［J］.General Thoracic and Cardiovascular Surgery，2014，62(6)：351-356.
[15]Iyoda A，Hiroshima K，Moriya Y，et al.Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma［J］.Annals of Thoracic Surgery，2006，82(5)：1802-1807.
[16]Hiroshima K，Mino-Kenudson M.Update on large cell neuroendocrine carcinoma［J］.Translational Lung Cancer Research，2017，6(5)：530-539.
[17]Hiroshima K，Iyoda A，Shida T，et al.Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma：A morphological，immunohistochemical，and molecular analysis［J］.Modern Pathology，2006，19(10)：1358-1368.
[18]Asamura H，Kameya T，Matsuno Y，et al.Neuroendocrine neoplasms of the lung：A prognostic spectrum［J］.Journal of Clinical Oncology，2006，24(1)：70-76.
[19]Derks JL，Hendriks LE，Buikhuisen WA，et al.Clinical features of large cell neuroendocrine carcinoma：A population-based overview［J］.European Respiratory Journal，2016，47(2)：615-624.
[20]Welter S，Aigner C，Roesel C.The role of surgery in high grade neuroendocrine tumours of the lung［J］.Journal of Thoracic Disease，2017，9(Suppl 15)：S1474-S1483.
[21]Zhou F，Hou L，Ding T，et al.Distinct clinicopathologic features，genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma：From different origin cells［J］？Lung Cancer(Amsterdam，Netherlands)，2018，116(30)：30-37.
[22]Lou G，Yu X，Song Z.Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma［J］.Clinical Lung Cancer，2017，18(3)：e197-e201.
[23]Sakurai H，Asamura H.Large-cell neuroendocrine carcinoma of the lung：Surgical management［J］.Thoracic Surgery Clinics，2014，24(3)：305-311.
[24]Rieber J，Schmitt J，Warth A，et al.Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas［J］.European Journal of Medical Research，2015，20(64)：1-8.
[25]Eichhorn F，Dienemann H，Muley T，et al.Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung［J］.Annals of Thoracic Surgery，2015，99(3)：983-989.
[26]Roesel C，Terjung S，Weinreich G，et al.A single-institution analysis of the surgical management of pulmonary large cell neuroendocrine carcinomas［J］.Annals of Thoracic Surgery，2016，101(5)：1909-1914.
[27]Tanaka Y，Ogawa H，Uchino K，et al.Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma：A possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy［J］.Journal of Thoracic and Cardiovascular Surgery，2013，145(3)：839-846.
[28]Grand B，Cazes A，Mordant P，et al.High grade neuroendocrine lung tumors：pathological characteristics，surgical management and prognostic implications［J］.Lung Cancer(Amsterdam，Netherlands)，2013，81(3)：404-409.
[29]Nakajima T，Yasufuku K.How I do it-optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples［J］.Journal of Thoracic Oncology，2011，6(1)：203-206.
[30]Saji H，Tsuboi M，Matsubayashi J，et al.Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy［J］.Anti-Cancer Drugs，2010，21(1)：89-93.
[31]Abedallaa N，Tremblay L，Baey C，et al.Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma［J］.Journal of Thoracic Oncology，2012，7(7)：1179-1183.
[32]Sun JM，Ahn MJ，Ahn JS，et al.Chemotherapy for pulmonary large cell neuroendocrine carcinoma：Similar to that for small cell lung cancer or non-small cell lung cancer［J］? Lung Cancer(Amsterdam，Netherlands)，2012，77(2)：365-370.
[33]Niho S，Kenmotsu H，Sekine I，et al.Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung：A multicenter phase II study［J］.Journal of Thoracic Oncology，2013，8(7)：980-984.
[34]Derks JL，Leblay N，Thunnissen E，et al.Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome［J］.Clinical Cancer Research，2018，24(1)：33-42.
[35]Makino T，Mikami T，Hata Y，et al.Comprehensive biomarkers for personalized treatment in pulmonary large cell neuroendocrine carcinoma：A comparative analysis with adenocarcinoma［J］.The Annals of Thoracic Surgery，2016，102(5)：1694-1701.
[36]Derks JL，Leblay N，Lantuejoul S，et al.New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas，and the impact on their clinical management［J］.Journal of Thoracic Oncology，2018，13(6)：752-766.
[37]Christopoulos P，Engel-riedel W，Grohe C，et al.Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma：A multicenter phase II trial［J］.Annals of Oncology，2017，28(8)：1898-1902.
[38]Derks JL，Van Suylen RJ，Thunnissen E，et al.Chemotherapy for pulmonary large cell neuroendocrine carcinomas：Does the regimen matter［J］？European Respiratory Journal，2017，49(6)：838-847.
[39]Le Treut J，Sault MC，Lena H，et al.Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma：The GFPC 0302 study［J］.Annals of Oncology，2013，24(6)：1548-1552.
[40]Wang Y，Shen YH，Ma S，et al.A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation：A case report［J］.Oncology Letters，2015，10(3)：1575-1578.
[41]Yokouchi H，Kitahashi M，Oshitari T，et al.Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung［J］.Graefe's Archive for Clinical and Experimental Ophthalmology，2013，251(9)：2243-2245.
[42]Odate S，Onishi H，Nakamura K，et al.Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma［J］.Anticancer Research，2013，33(9)：3699-3703.
[43]Iyoda A，Travis WD，Sarkaria IS，et al.Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma［J］.Experimental and Therapeutic Medicine，2011，2(6)：1041-1045.
[44]Odate S，Nakamura K，Onishi H，et al.TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma［J］.Lung Cancer(Amsterdam，Netherlands)，2013，79(3)：205-214.
[45]Kim HS，Lee JH，Nam SJ，et al.Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung［J］.Journal of Thoracic Oncology，2018，13(5)：636-648.
[46]Weber MM，Fottner C.Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia［J］.Oncology Research and Treatment，2018，41(5)：306-312.